Luminex Corporation Company Profile (NASDAQ:LMNX)

About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web:
  • Market Cap: $895.08 million
  • Outstanding Shares: 44,071,000
Average Prices:
  • 50 Day Moving Avg: $19.90
  • 200 Day Moving Avg: $20.00
  • 52 Week Range: $17.64 - $22.27
  • Trailing P/E Ratio: 63.22
  • Foreward P/E Ratio: 30.31
  • P/E Growth: 0.70
Sales & Book Value:
  • Annual Revenue: $297.73 million
  • Price / Sales: 3.01
  • Book Value: $9.68 per share
  • Price / Book: 2.10
  • Annual Dividend: $0.24
  • Dividend Yield: 1.2%
  • EBITDA: $49.82 million
  • Net Margins: 4.72%
  • Return on Equity: 4.81%
  • Return on Assets: 4.37%
  • Current Ratio: 5.70%
  • Quick Ratio: 4.30%
  • Average Volume: 152,469 shs.
  • Beta: 0.28
  • Short Ratio: 11.22

Frequently Asked Questions for Luminex Corporation (NASDAQ:LMNX)

What is Luminex Corporation's stock symbol?

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex Corporation pay dividends? What is the dividend yield for Luminex Corporation?

Luminex Corporation announced a quarterly dividend on Tuesday, September 12th. Investors of record on Friday, September 22nd will be given a dividend of $0.06 per share on Friday, October 13th. This represents a $0.24 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Thursday, September 21st. View Luminex Corporation's Dividend History.

How were Luminex Corporation's earnings last quarter?

Luminex Corporation (NASDAQ:LMNX) released its earnings results on Monday, August, 7th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.11. The business had revenue of $76.50 million for the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The firm's revenue was up 19.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 earnings per share. View Luminex Corporation's Earnings History.

When will Luminex Corporation make its next earnings announcement?

Luminex Corporation is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Luminex Corporation.

Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?

4 analysts have issued twelve-month price objectives for Luminex Corporation's shares. Their predictions range from $18.00 to $21.00. On average, they expect Luminex Corporation's stock price to reach $19.33 in the next twelve months. View Analyst Ratings for Luminex Corporation.

What are analysts saying about Luminex Corporation stock?

Here are some recent quotes from research analysts about Luminex Corporation stock:

  • 1. According to Zacks Investment Research, "Luminex’s second quarter saw a strong top line, solid cash flow and soaring profits. The company also beat the Zacks Consensus Estimates on both lines. Luminex’s Assay business is likely to be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory front in the second quarter. In this regard, the recent CE-IVD mark for the ARIES Norovirus Assay,  the FDA approval of ARIES C. difficile Assay and the reimbursement approval of VERIGENE assay in Japan are noteworthy. Luminex is on the verge of completing its clinical study for Group A Strep and is close to submitting the same for FDA review. On the flipside, the company slashed its third-quarter revenue guidance. Luminex expects revenues at the segment to be impacted by funding challenges related to a multi-year bulk bead contract from a life science customer." (8/24/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex Corporation's key competitors?

Who are Luminex Corporation's key executives?

Luminex Corporation's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board
  • Nachum Shamir, President, Chief Executive Officer, Director
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary
  • Todd C. Bennett, Senior Vice President - Global Sales and Customer Operations
  • Nancy M. Fairchild, Senior Vice President - Human resources
  • Tadd S. Lazarus M.D., Senior Vice President
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality
  • Robert J. Cresci, Independent Director
  • Stephen L. Eck, Independent Director

How do I buy Luminex Corporation stock?

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex Corporation's stock price today?

One share of Luminex Corporation stock can currently be purchased for approximately $20.31.

MarketBeat Community Rating for Luminex Corporation (NASDAQ LMNX)
Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Luminex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Luminex Corporation (NASDAQ:LMNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $19.33 (4.81% downside)
Consensus Price Target History for Luminex Corporation (NASDAQ:LMNX)
Price Target History for Luminex Corporation (NASDAQ:LMNX)
Analysts' Ratings History for Luminex Corporation (NASDAQ:LMNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017Jefferies Group LLCReiterated RatingHold$21.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016J P Morgan Chase & CoUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Luminex Corporation (NASDAQ:LMNX)
Earnings by Quarter for Luminex Corporation (NASDAQ:LMNX)
Earnings History by Quarter for Luminex Corporation (NASDAQ LMNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.03N/AView Earnings Details
8/7/2017Q2 2017$0.09$0.20$75.45 million$76.50 millionViewListenView Earnings Details
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Luminex Corporation (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.22
2018 EPS Consensus Estimate: $0.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.03$0.03$0.03
Q4 20171$0.04$0.04$0.04
Q1 20181$0.13$0.13$0.13
Q2 20181$0.11$0.11$0.11
Q3 20181$0.11$0.11$0.11
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Current Dividend Information for Luminex Corporation (NASDAQ:LMNX)
Most Recent Dividend:10/13/2017
Annual Dividend:$0.24
Dividend Yield:1.18%
Payout Ratio:75.00% (Trailing 12 Months of Earnings)
45.28% (Based on This Year's Estimates)
35.82% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex Corporation (NASDAQ:LMNX)

Dividend History by Quarter for Luminex Corporation (NASDAQ LMNX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex Corporation (NASDAQ:LMNX)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 78.12%
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017Robert J CresciDirectorSell19,631$18.98$372,596.38View SEC Filing  
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Luminex Corporation (NASDAQ:LMNX)
Latest Headlines for Luminex Corporation (NASDAQ:LMNX)
DateHeadline logoHere's Why Investors Should Sell Patterson Companies Now - October 16 at 8:16 PM logoHere's Why Investors Should Sell Patterson Companies Now - October 16 at 8:16 PM logoLuminex Corporation (LMNX) versus Varian Medical Systems (VAR) Head-To-Head Comparison - October 13 at 2:26 AM logoDaVita Banks on Acquisitions, Escalating Expenses a Concern - October 9 at 4:30 PM logoLuminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017 - October 9 at 4:30 PM logoLuminex Corporation (LMNX) vs. ResMed (RMD) Head to Head Analysis - October 8 at 12:22 AM logoFinancial Survey: Zeltiq Aesthetics (ZLTQ) and Luminex Corporation (LMNX) - October 7 at 6:28 PM logoStrategy To YieldBoost LMNX To 9.5% Using Options - October 6 at 3:36 AM logoBio-Techne's New Simple Plex Cartridge Boosts Protein Segment - September 28 at 6:36 PM logoLuminex Corp. – Value Analysis (NASDAQ:LMNX) : September 26, 2017 - September 26 at 5:48 PM logoLuminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : September 25, 2017 - September 25 at 8:38 AM logo$74.22 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter - September 24 at 7:54 AM logoLuminex Corporation (LMNX) Receives Average Rating of "Hold" from Analysts - September 23 at 12:36 PM logoLuminex Corporation To Present At Cantor Fitzgerald's Global Healthcare Conference - September 20 at 2:30 AM logoCritical Survey: Luminex Corporation (LMNX) and Alere (ALR) - September 18 at 12:02 PM logoLuminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : September 14, 2017 - September 15 at 6:05 AM logoLuminex Corporation (LMNX) Announces Quarterly Dividend of $0.06 - September 13 at 3:30 PM logoLuminex Corporation Declares Third Quarter Cash Dividend - September 13 at 5:54 AM logoLuminex declares $0.06 dividend - September 12 at 9:00 AM logoLuminex (LMNX) Down 2.5% Since Earnings Report: Can It Rebound? - September 8 at 1:46 AM logo$0.03 EPS Expected for Luminex Corporation (LMNX) This Quarter - September 3 at 2:30 PM logoLuminex Corporation and Sutter Health Collaborate to Improve Patient Care - August 30 at 6:08 AM logoLuminex Corporation (LMNX) Receives Average Rating of "Hold" from Brokerages - August 29 at 3:12 PM logoQ4 2017 Earnings Forecast for Luminex Corporation Issued By Jefferies Group (LMNX) - August 25 at 10:08 AM logoRobert J. Cresci Sells 19,631 Shares of Luminex Corporation (LMNX) Stock - August 24 at 1:26 PM logoQ3 2017 EPS Estimates for Luminex Corporation Cut by Jefferies Group (LMNX) - August 24 at 6:26 AM logoETFs with exposure to Luminex Corp. : August 21, 2017 - August 22 at 8:34 PM logoLuminex Corp. :LMNX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 - August 11 at 6:10 AM logoLuminex Corporation (NASDAQ:LMNX) Downgraded by TheStreet to C+ - August 9 at 9:10 AM logoLuminex's (LMNX) CEO Homi Shamir on Q2 2017 Results - Earnings Call Transcript - August 9 at 1:24 AM logoEdited Transcript of LMNX earnings conference call or presentation 7-Aug-17 8:30pm GMT - August 8 at 8:20 PM logoLuminex Corporation Reports Second Quarter 2017 Financial Results - August 7 at 8:53 PM logoLuminex tops Street 2Q forecasts - August 7 at 8:53 PM logoLuminex Corporation (LMNX) Announces Earnings Results, Beats Expectations By $0.15 EPS - August 7 at 8:08 PM logoLuminex Breaks Below 200-Day Moving Average - Notable For LMNX - August 5 at 7:15 PM logoLuminex Corp. – Value Analysis (NASDAQ:LMNX) : August 5, 2017 - August 5 at 1:38 AM logoLuminex Corporation (NASDAQ:LMNX) Given Average Rating of "Hold" by Analysts - August 4 at 3:00 PM logoLuminex Corporation (LMNX) vs. Biolase (BIOL) Head to Head Contrast - July 31 at 10:30 AM logoLuminex Corporation (NASDAQ:LMNX) Scheduled to Post Earnings on Monday - July 31 at 8:47 AM logo$75.18 Million in Sales Expected for Luminex Corporation (NASDAQ:LMNX) This Quarter - July 30 at 7:18 AM logo Brokerages Anticipate Luminex Corporation (LMNX) Will Announce Earnings of $0.11 Per Share - July 28 at 10:24 PM logoLuminex Corp. (LMNX) Granted FDA Clearance for ARIES C. Difficile Assay - July 25 at 2:53 AM logoETFs with exposure to Luminex Corp. : July 24, 2017 - July 25 at 2:53 AM logoLuminex Corporation Receives FDA Clearance for ARIES C. difficile Assay - July 24 at 11:38 AM logoLuminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : July 24, 2017 - July 24 at 11:38 AM logoHead to Head Review: LeMaitre Vascular (LMAT) versus Luminex Corporation (LMNX) - July 20 at 10:16 PM logoLuminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017 - July 17 at 12:57 PM logoETFs with exposure to Luminex Corp. : July 14, 2017 - July 15 at 6:01 AM logoLuminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : July 10, 2017 - July 11 at 12:22 AM logoLuminex Corporation (NASDAQ:LMNX) Given Average Recommendation of "Hold" by Brokerages - July 10 at 3:08 PM



Luminex Corporation (LMNX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.